Beware of callers impersonating MyMichigan Health asking for credit card information. If you receive a suspicious call, request a call back number if possible and report that information to our security team at (989) 839-1911.

Learn More

Cancer Clinical Trials at MyMichigan Health

Clinical research studies serve to improve cancer treatment and ensure the highest possible level of patient care. Patients involved in research studies play an important role in advancing evidence-based medicine to future patients. There are tremendous advantages for patients having access to nationally sponsored clinical trials closer to home including treatment options that might otherwise not be available to them and by avoiding treatment delays and decreasing lengthy travel times. Patients are eligible to participate in research studies only after specific eligibility criteria have been met.

Current Cancer Clinical Trials at MyMichigan

Breast Cancer

  • ALLIANCE A011401 (BWEL TRIAL) 
    Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer.
    • Enrollment goal met. Patients in follow-up until 2030
    • NCT: 02750826
  • ASPEN - Dr. Levandowski
    Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer.
    • Enrollment Open.
    • NCT: 05568472

  • IBCSG 24-02 
    A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women With Endocrine Responsive Breast Cancer

    • Enrollment goal met. Patient(s) in follow-up until death
    • NCT: 00066690

  • NSABP B-47 
    A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer

    • Enrollment goal met.
    • Follow-up completed. Awaiting closeout. 
    • NCT: 01275677

  • PACCT-1 
    Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial

    • Enrollment goal met, Patient(s) in follow-up until 2027
    • NCT: 00310180

  • S1007 
    A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer

    • Enrollment goal met. Patient(s) in follow-up until 2028
    • NCT: 01272037
  • SWOG 1418 
    A randomized phase III trial to evaluate the efficacy and safety of MK-3475 as adjuvant therapy for triple receptor negative breast cancer with ≥ 1cm residual invasive cancer or positive lymph nodes after neoadjuvant chemotherapy.
    • Enrollment goal met. Patients in follow-up until 2029
    • NCT: 02954874

Lung Cancer

  • ALCHEMIST TRIAL 
    • ALLIANCE A151216
      Adjuvant lung cancer enrichment marker identification and sequencing trial. Only Squamous now.
    • A081105 
      Randomized double blind placebo controlled study of Erlotinib or placebo in patients with completely resected epidermal growth factor mutant non-small cell lung cancer.
      • Enrollment goals met. Patients in follow-up until 2030
      • NCT: 02193282
    • EA5142 
      A randomized phase III study of Nivolumab after surgical resection and adjuvant chemotherapy in non-small cell lung cancers.
      • Enrollment goal met.
      • Patients in follow-up until 2029
      • NCT: 02595944

Multiple Myeloma

  • E1A11 
    A randomized phase III trial of Bortezomib, Lenalidomide, and Dexamethasone verses Carfilzomib, Lenalidomide, and Dexamethasone followed by limited or indefinite duration Lenalidomide maintenance in patients with newly diagnosed symptomatic multiple myeloma.
    • Enrollment goals met. Patients in follow-up until 2029
    • NCT: 01863550

Other

  • PROSPECT N1048 
    A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision

    • Enrollment goal met. Patients in follow-up until 2023
    • NCT: 01515787

Participate in a Clinic Research Trial

To participate in Clinical Research Trial, please call our office at (989) 631-2469 or email us at cvresearch@mymichigan.org.

Related Providers